Long-Acting PrEP Status Update
Updated as of October 2025
This dashboard provides a timely snapshot on the progress of accelerating access to long-acting PrEP products. The graphics featured here track regulatory approvals, volumes, ongoing and planned implementation science studies, and non-profit prices for approved longer-acting PrEP products, including injectable cabotegravir, injectable lenacapavir, and the dapivirine vaginal ring. The dashboard is updated quarterly by AVAC, Secretariat to the Coalition to Accelerate Access to Long-Acting PrEP.
The Pathway to Access and Impact
This graphic outlines the critical steps for rolling out long-acting injectable PrEP products.
